Latest advances in extracellular vesicles: from bench to bedside
Source abstract
Abstract
Extracellular vesicles (EVs) are small membraned vesicles and approximately 50-150 nm in diameter. Almost all of the type of cells releases the EVs and circulates in the body fluids. EVs contain multiple functional components, such as mRNAs, microRNAs (miRNAs), DNAs, and proteins, which can be transferred to the recipient cells, resulting in phenotypic changes. Recently, EV research has focused on their potential as a drug delivery vehicle and in targeted therapy against specific molecules. Moreover, some surface proteins are specific to particular diseases, and therefore, EVs also have promise as biomarkers. In this concise review, we summarize the latest research focused on EVs, which have the potential to become a promising drug delivery method, biomarker, and new therapeutic target for improving the outcomes of cancer patients.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan
Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan
Department of Translational Research for Extracellular Vesicles, Tokyo Medical University, Tokyo, Japan
Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan
Funding
Japan Agency for Medical Research and Development · Kobayashi Foundation for Cancer Research
References (100+)
Show source-provided references
1. 10.1242/jcs.113.19.336510.1242/jcs.113.19.3365 ↗
2. 10.1083/jcb.20121113810.1083/jcb.201211138 ↗
3. 10.3402/jev.v4.2706610.3402/jev.v4.27066 ↗
4. 10.1016/j.tcb.2015.01.00410.1016/j.tcb.2015.01.004 ↗
5. 10.1016/j.tcb.2008.11.00310.1016/j.tcb.2008.11.003 ↗
6. 10.3389/fgene.2013.0017310.3389/fgene.2013.00173 ↗
7. 10.1038/ncb159610.1038/ncb1596 ↗
8. 10.1073/pnas.091484310710.1073/pnas.0914843107 ↗
9. 10.1074/jbc.M111.28866210.1074/jbc.M111.288662 ↗
10. 10.1016/j.molcel.2010.06.01010.1016/j.molcel.2010.06.010 ↗
11. 10.1074/jbc.M110.10782110.1074/jbc.M110.107821 ↗
12. 10.1038/ncomms1528710.1038/ncomms15287 ↗
13. 10.1093/intimm/dxh26710.1093/intimm/dxh267 ↗
14. 10.1007/978-1-60761-711-2_610.1007/978-1-60761-711-2_6 ↗
15. 10.1371/journal.pone.000857710.1371/journal.pone.0008577 ↗
16. 10.1136/thoraxjnl-2018-21189710.1136/thoraxjnl-2018-211897 ↗
17. 10.4049/jimmunol.179.3.196910.4049/jimmunol.179.3.1969 ↗
18. 10.1002/pros.2086010.1002/pros.20860 ↗
19. 10.1098/rstb.2014.018310.1098/rstb.2014.0183 ↗
20. 10.3402/jev.v2i0.2042410.3402/jev.v2i0.20424 ↗
21. 10.1586/epr.09.1710.1586/epr.09.17 ↗
22. 10.1073/pnas.152123011310.1073/pnas.1521230113 ↗
23. Konoshenko MY · Biomed Res Int · 2018 · 8545347
24. 10.1186/s12934-017-0856-910.1186/s12934-017-0856-9 ↗
25. 10.1186/s12967-017-1374-610.1186/s12967-017-1374-6 ↗
26. 10.1186/s13287-018-0923-010.1186/s13287-018-0923-0 ↗
27. 10.1039/C8NR02871K10.1039/C8NR02871K ↗
28. Théry C · Curr Protoc Cell Biol · 2006 · 3 · 3
29. 10.1371/journal.pone.018653410.1371/journal.pone.0186534 ↗
30. 10.1016/j.ymeth.2015.04.00810.1016/j.ymeth.2015.04.008 ↗
31. 10.1007/978-1-4939-6728-5_710.1007/978-1-4939-6728-5_7 ↗
32. 10.1007/978-1-4939-7652-2_910.1007/978-1-4939-7652-2_9 ↗
33. 10.1007/978-1-4939-7652-2_710.1007/978-1-4939-7652-2_7 ↗
34. 10.1080/20013078.2018.149014310.1080/20013078.2018.1490143 ↗
35. 10.1038/srep1731910.1038/srep17319 ↗
36. 10.1038/srep3393510.1038/srep33935 ↗
37. 10.1073/pnas.170921011410.1073/pnas.1709210114 ↗
38. 10.1038/onc.2014.30010.1038/onc.2014.300 ↗
39. 10.1016/j.canlet.2018.08.00110.1016/j.canlet.2018.08.001 ↗
40. 10.1080/20013078.2017.135947910.1080/20013078.2017.1359479 ↗
41. 10.1038/s41467-017-02583-010.1038/s41467-017-02583-0 ↗
42. 10.1038/s41467-018-07810-w10.1038/s41467-018-07810-w ↗
43. 10.1038/ncomms771610.1038/ncomms7716 ↗
44. Shtam T · Breast Cancer Res Treat
45. 10.1016/0360-3016(83)90179-710.1016/0360-3016(83)90179-7 ↗
46. 10.18632/oncotarget.2237110.18632/oncotarget.22371 ↗
47. 10.1073/pnas.170486211410.1073/pnas.1704862114 ↗
48. 10.1126/scisignal.200523110.1126/scisignal.2005231 ↗
49. 10.1016/j.canlet.2018.06.04110.1016/j.canlet.2018.06.041 ↗
50. 10.1007/s13277-015-4313-210.1007/s13277-015-4313-2 ↗
51. Xiao H · Cell Commun Signal · 2014 · 12 · 64
52. 10.1093/carcin/bgx04510.1093/carcin/bgx045 ↗
53. 10.1038/s41586-018-0392-810.1038/s41586-018-0392-8 ↗
54. 10.1038/nrclinonc.2014.17210.1038/nrclinonc.2014.172 ↗
55. 10.1177/107815521349863010.1177/1078155213498630 ↗
56. 10.1016/j.nano.2016.03.00210.1016/j.nano.2016.03.002 ↗
57. 10.1016/j.colsurfb.2015.07.01310.1016/j.colsurfb.2015.07.013 ↗
58. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
59. 10.1021/acsami.7b1359410.1021/acsami.7b13594 ↗
60. 10.1016/j.biomaterials.2017.09.02010.1016/j.biomaterials.2017.09.020 ↗
61. 10.1167/tvst.5.2.1110.1167/tvst.5.2.11 ↗
62. Fujimori K · Cancer Res · 1989 · 49 · 5656
63. 10.2217/nnm-2016-010210.2217/nnm-2016-0102 ↗
64. 10.1016/j.addr.2016.02.00610.1016/j.addr.2016.02.006 ↗
65. 10.1038/mt.2012.18010.1038/mt.2012.180 ↗
66. 10.1038/mt.2010.10510.1038/mt.2010.105 ↗
67. 10.1016/j.nano.2018.05.02010.1016/j.nano.2018.05.020 ↗
68. Hatzidaki E · Anticancer Drugs
69. 10.1038/mt.2011.16410.1038/mt.2011.164 ↗
70. 10.1016/j.jconrel.2015.03.03310.1016/j.jconrel.2015.03.033 ↗
71. 10.1186/1478-811X-11-8810.1186/1478-811X-11-88 ↗
72. 10.1038/nprot.2012.13110.1038/nprot.2012.131 ↗
73. 10.1038/nbt.180710.1038/nbt.1807 ↗
74. 10.1038/srep3854110.1038/srep38541 ↗
75. 10.1038/srep2193310.1038/srep21933 ↗
76. 10.1039/C8SC03224F10.1039/C8SC03224F ↗
77. 10.1002/advs.20170061110.1002/advs.201700611 ↗
78. 10.1038/nature2234110.1038/nature22341 ↗
79. ClinicalTrials.gov Identifier: NCT03608631 https://clinicaltrials.gov/ct2/show/NCT03608631?term=exosome&cntry=US&state=US%3ATX&rank=1
80. 10.1038/s41598-018-29780-110.1038/s41598-018-29780-1 ↗
81. 10.1080/20013078.2018.144013210.1080/20013078.2018.1440132 ↗
82. 10.1038/nm0598-59410.1038/nm0598-594 ↗
83. 10.1080/21645515.2016.115724410.1080/21645515.2016.1157244 ↗
84. 10.1073/pnas.150579911210.1073/pnas.1505799112 ↗
85. 10.1038/s41598-018-25515-410.1038/s41598-018-25515-4 ↗
86. 10.1016/j.jhep.2019.03.00610.1016/j.jhep.2019.03.006 ↗
87. 10.1016/j.vaccine.2019.02.00410.1016/j.vaccine.2019.02.004 ↗
88. 10.18632/oncotarget.2480910.18632/oncotarget.24809 ↗
89. Hallal S, Russell BP, Wei H, et al. Extracellular vesicles from neurosurgical aspirates identifies chaperonin containing TCP1 subunit 6A (CCT6A) as a potential glioblastoma biomarker with prognostic significance, tumor-derived EVs as a novel source of protein biomarkers for cancer diagnosis and monitoring. Proteomics. 2019;19:e1800157.10.1002/pmic.201800157 ↗
90. 10.1038/ncb180010.1038/ncb1800 ↗
91. 10.1182/blood-2016-09-74229610.1182/blood-2016-09-742296 ↗
92. 10.1038/ncomms1447010.1038/ncomms14470 ↗
93. 10.1039/C8LC01071D10.1039/C8LC01071D ↗
94. 10.1039/C8LC01185K10.1039/C8LC01185K ↗
95. 10.1038/s41591-018-0230-410.1038/s41591-018-0230-4 ↗
96. 10.1021/acsnano.7b0819910.1021/acsnano.7b08199 ↗
97. 10.1021/acs.analchem.8b0018910.1021/acs.analchem.8b00189 ↗
98. 10.1038/nbt.288610.1038/nbt.2886 ↗
99. 10.1038/s41598-018-27203-910.1038/s41598-018-27203-9 ↗
100. 10.3389/fimmu.2018.0158310.3389/fimmu.2018.01583 ↗